the Rest Peptide Mechanism Weight Loss Potential Typical Use Cagrilintide Amylin analog Moderate to high (especially in combo) Weight loss adjunct Semaglutide GLP-1 agonist High Obesity, type 2 diabetes Tirzepatide GIP/GLP-1 dual agonist Very high Obesity, type 2 diabetes Retatrutide GIP/GLP-1/Glucagon triple agonist Extremely high (research stage) Experimental weight loss agent Future of Cagrilintide and Its Dosage Schedules As the body of research grows, Cagrilintide dosage schedules will likely become more refined based on user response and clinical trials
Definitions of all these variables using administrative claims are described in Additional file 1: Table S1
Its mechanism of action includes stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, and slowing gastric emptyingall of which contribute to improved glycemic profiles in experimental systems
They are often injectable medications that are combined with other treatmentssuch as diet, exercise, medication, or bariatric surgeryto promote weight loss and manage blood sugar levels
For example, patients using semaglutide experienced an average weight loss of 14.9% over 68 weeks
Hydrogenation was completed using the AutoDock (version 1.5.7), and the molecular docking processes were achieved through AutoDock Vina (version 1.2.5) with the grid boxes parameters (Table S2)